Endogenous EP4 prostaglandin receptors coupled positively to adenylyl cyclase in Chinese hamster ovary cells:: pharmacological characterization

被引:29
作者
Crider, JY [1 ]
Griffin, BW [1 ]
Sharif, NA [1 ]
机构
[1] Alcon Res Ltd, Mol Pharmacol Unit, Ft Worth, TX 76134 USA
来源
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS | 2000年 / 62卷 / 01期
关键词
D O I
10.1054/plef.1999.0120
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The purpose of these studies was to investigate the pharmacology of E-series and selected prostaglandins of other classes on adenylyl cyclase activity in Chinese hamster ovary (CHO) cells expressing an endogenous prostanoid receptor and to compare these responses with those from immortalized human nonpigmented ciliary epithelial (NPE) cells containing the EP2 receptor. 11-deoxy-PGE(2) was the most potent of the 16 prostanoid agonists tested for stimulating cAMP formation with a potency (EC50) value of 26 +/- 6 nM in the CHO cells. The endogenous ligand, PGE(2), exhibited potencies of 40 +/- 7 nM (n = 24) in the CHO cells and 67 +/- 9 nM (n = 46) in the NPE cells. The EP2 receptor agonist, butaprost, produced an EC50 value of 212 +/- 58 nM (n = 4) in the NPE cells while being inactive (EC50 > 10 000 nM, n = 6) in the CHO cells. The EP2 receptor selective antagonists, AH22921 and AH23848B, at a concentration of 30 mu M, caused a 2.2 +/- 0.5 (n = 4) and 8.2 +/- 2.7 (n = 4) fold rightward shift in the PGE(2) concentration-response curves in the CHO cells, yielding apparent pK(b) values of 4.6 +/- 0.6 and 5.3 +/- 0.2 (n = 4), respectively. AH22921 and AH23848B were non-competitive antagonists at the CHO cell EP2 receptor, but did not shift the PGE(2) concentration-response curves in the NPE cells containing the EP2 receptor. These studies have characterized the functional prostaglandin receptors in CHO cells pharmacologically and shown them to be consistent with the EP4 subtype. (C) 2000 harcourt Publishers Ltd.
引用
收藏
页码:21 / 26
页数:6
相关论文
共 23 条
[1]  
BASTIEN L, 1994, J BIOL CHEM, V269, P11873
[2]  
BOIE Y, 1997, FASEB J, V11, pA1138
[3]   Differential localization of prostaglandin E receptor subtypes in human kidney [J].
Breyer, MD ;
Davis, L ;
Jacobson, HR ;
Breyer, RM .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL FLUID AND ELECTROLYTE PHYSIOLOGY, 1996, 270 (05) :F912-F918
[4]   A NOVEL INHIBITORY PROSTANOID RECEPTOR IN PIGLET SAPHENOUS-VEIN [J].
COLEMAN, RA ;
GRIX, SP ;
HEAD, SA ;
LOUTTIT, JB ;
MALLETT, A ;
SHELDRICK, RLG .
PROSTAGLANDINS, 1994, 47 (02) :151-168
[5]  
COLEMAN RA, 1994, PHARMACOL REV, V46, P205
[6]   Prostaglandin DP receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EBTr) cells: pharmacological characterization using agonists and antagonists [J].
Crider, JY ;
Griffin, BW ;
Sharif, NA .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 127 (01) :204-210
[7]   Use of a semi automated, robotic radioimmunoassay to measure cAMP generated by activation of DP-, EP2-, and IP-prostaglandin receptors in human ocular and other cell types [J].
Crider, JY ;
Griffin, BW ;
Xu, SX ;
Sharif, NA .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1998, 59 (01) :77-82
[8]   Prostaglandin-stimulated adenylyl cyclase activity via a pharmacologically defined EP2 receptor in human nonpigmented ciliary epithelial cells [J].
Crider, JY ;
Griffin, BW ;
Sharif, NA .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 1998, 14 (04) :293-304
[9]  
deBrumFernandes AJ, 1996, BRIT J PHARMACOL, V118, P1597, DOI 10.1111/j.1476-5381.1996.tb15580.x
[10]  
FURCHGOTT RF, 1972, HDB EXPT PHARM, V33, P293